title: Imatinib mesylate-induced long-term remission in extra-medullary T-cell lymphoid blastic phase of chronic myelogenous leukemia.
authors.forename: Jan A
authors.initials: JA
authors.lastname: Burger
authors.forename: Annette
authors.initials: A
authors.lastname: Schmitt-Gräff
authors.forename: Andrea
authors.initials: A
authors.lastname: Bürkle
authors.forename: Lysann
authors.initials: L
authors.lastname: Seiler
authors.forename: Jürgen
authors.initials: J
authors.lastname: Finke
mesh_terms: D001549:Benzamides; D001706:Biopsy; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology*; D008198:Lymph Nodes / Q000187:drug effects / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013997:Time Factors; D015898:Tomography Scanners, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate